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SObjectives: Gastroesophageal reflux disease (GERD) is implicated as a risk factor for bronchiolitis obliterans
syndrome after lung transplantation, but its effects on acute rejection, early allograft function, and survival are
unclear. Therefore, we sought to systematically understand the time-related impact of pretransplant GERD on
graft function (spirometry), mortality, and acute rejection early after lung transplantation.
Methods: From January 2005 to July 2008, 215 patients underwent lung transplantation; 114 had preoperative
pH testing, and 32 (28%) had objective evidence of GERD. Lung function was assessed by forced 1-second
expiratory volume (FEV1; percent of predicted) in 97 patients, mortality by follow-up (median, 2.2 years),
and acute rejection by transbronchial biopsy.
Results: Pretransplant GERD was associated with decreased FEV1 early after lung transplantation (P ¼ .01)
such that by 18 months, FEV1 was 70% of predicted in double lung transplant patients with GERD versus
83% among non-GERD patients (P ¼ .05). A similar decrease was observed in single lung transplantation
(50% vs 60%, respectively; P ¼ .09). GERD patients had lower survival early after transplant ( P ¼ .02)—
75% versus 90%. Presence of GERD did not affect acute rejection (P ¼ .6).
Conclusions: For lung transplant recipients, pretransplant GERD is associated with worse early allograft func-
tion and survival, but not increased acute rejection. The compromise in lung function is substantial, such that
FEV1 after double lung transplant in GERD patients approaches that of single lung transplant in non-GERD pa-
tients.We advocate thorough testing for GERDbefore lung transplantation; if identified, aggressive therapy early
after transplant, including fundoplication, may prove efficacious. (J Thorac Cardiovasc Surg 2011;142:47-52)Supplemental material is available online.
Gastroesophageal reflux has been implicated as a risk factor
for late allograft dysfunction after lung transplantation.1,2
This association is strengthened by reports demonstrating
that fundoplication early after transplantation has
a protective effect from bronchiolitis obliterans syndrome
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The Journal of Thoracic and Cyet translated into an obvious survival advantage, and pres-
ervation of spirometry in this setting has not been evaluated.
Consequently, the belief that reflux negatively affects out-
come of transplantation is not yet universally accepted.
Moreover, early impact of preexisting gastroesophageal re-
flux disease (GERD) has not been studied. Therefore, we
sought to systematically understand the time-related impact
of pretransplant GERD on graft function (spirometry), mor-
tality, and acute rejection early after lung transplantation.PATIENTS AND METHODS
From January 2005 to July 2008, 215 patients underwent lung transplan-
tation at Cleveland Clinic. Beginning in 2005, an attempt was made to as-
sess GERD and esophageal and gastric motility before listing for lung
transplantation. It was not possible to test all patients because of acuity
of illness, inability to tolerate assessment, and lack of payor authorization.
Although some of these tests were performed at Cleveland Clinic, in nu-
merous cases they were performed at referring institutions because of these
constraints. In total, 114 patients underwent at least ambulatory pH assess-
ment, and they constitute the study group. No patient underwent fundopli-
cation after transplant for the duration of the study. None was diagnosed
with scleroderma preoperatively.
Pretransplant GERD
GERD was considered for this study as a dichotomous diagnosis
because of heterogeneity of the raw data from multiple institutions.
Some reports of 24-hour pH testing expressed the results as simply positiveardiovascular Surgery c Volume 142, Number 1 47
Abbreviations and Acronyms
BOS ¼ bronchiolitis obliterans syndrome
FEV1 ¼ forced 1-second expiratory volume
FEV1% ¼ percent of predicted FEV1
GERD ¼ gastroesophageal reflux disease
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When quantitative data were available, GERD was defined as abnormali-
ties of percent recumbent reflux, total time of recumbent and upright reflux,
total number of reflux episodes in 24 hours, or elevated DeMeester score.
There was no attempt to compare raw data between institutions because
it was not possible to normalize across institutions. The lowest common ex-
pression from these 24-hour assessments was dichotomous: a diagnosis of
GERD or no GERD. It was recommended that pH studies be performed af-
ter discontinuing acid suppressing medications for at least 24 hours.
End Points
Spirometry. Of the 114 patients, 97 (85%) had at least 1 posttrans-
plant measurement at Cleveland Clinic of forced 1-second expiratory vol-
ume (FEV1), expressed as percent of predicted (FEV1%). A total of 871
assessments were available for analysis (Figure E1). These data were re-
trieved from the Pulmonary Function Laboratory Database. Median time
to spirometry was 4.4 months (15th and 85th percentiles; 1 and 13 months,
respectively).
Survival. Follow-up was 100% complete for all-cause mortality after
lung transplantation. A total of 212 patient-years of data were available
for analysis, with a median follow-up of 2.2 years; 10% of patients were
followed up for more than 3.3 years.
Acute rejection. All lung biopsy specimens were graded according to
the Lung Rejection Study Group classification system.4,5 This study
focused on perivascular rejection grades A0 through A4. Because of low
prevalence of grades A2 and above, these were combined into 1 group
for purposes of analysis. No patient in the study cohort had biopsy grade
A4. Early humoral rejection was not interrogated in these patients. To
reliably analyze the data and reduce confusion with BOS, we included
biopsy specimens only up to 1.5 years after transplant.
These data were retrieved from Cleveland Clinic pathology reports and
were recorded routinely in the Electronic Data Interface for Transplanta-
tion. A total of 725 biopsy records were available for 112 (98%) patients,
out of 114 who had a pH test result (Figure E2). The 2 patients with no
biopsy results died on the 27th and 90th day posttransplant.
Data
Data from the the Electronic Data Interface for Transplantation, Pulmo-
nary Function Laboratory Database, Pathology Database, and manually ex-
tracted GERD data were approved for use in research by the Cleveland
Clinic Institutional Review Board, with patient consent waived.
Data Analysis
GERD associations. Variables associated with pretransplant GERD
were identified by multivariable logistic regression using pretransplant var-
iables only (Appendix E1) and a bagging variable selection strategy.6 In
brief, automated stepwise regression was performed on 500 bootstrap
data sets, retaining variables with P  .05. Variables appearing in 50%
or more of the resulting 500 models (median rule) were considered reliable
risk factors.
To risk adjust outcomes after transplantation, we augmented this model
into a propensity model using variables occurring in 15% or more of boot-48 The Journal of Thoracic and Cardiovascular Surgestrap models.7-10 Variables identified by an asterisk in Appendix E1 were
included in this semisaturated model. Thereafter, a propensity score was
calculated for each patient for use in risk adjustment.
GERD and spirometry. The association of pretransplant GERD
and posttransplant FEV1 was investigated using a nonlinear cumulative
logit model with temporal decomposition into phases,11 with the assump-
tion of multinomial distribution. Three phases of temporal trend were iden-
tified for the odds of no rejection: an early constant phase, early to
intermediate peaking phase, and late rising phase, the latter approaching
an asymptote about 18 months after transplant. The resulting patient-
specific estimates were averaged to determine prevalence of each biopsy
grade over time.
GERD and survival. Survival was assessed nonparametrically by
the Kaplan-Meier method and parametrically by a multiphase hazard
model. The parametric model was used to resolve phases of instantaneous
risk of death (hazard function) and to estimate shaping parameters of
each.12 (For additional details, see http://www.clevelandclinic.org/ heart-
center/hazard.) Survival was estimated for 2 groups: (1) patients in our
study period (January 2005–July 2008), comparing those with and without
pH test results (Figure E3), and (2) patients with GERD compared with no
GERD. Effect of GERD on survival was assessed overall and after propen-
sity adjustment.
GERD and acute rejection. Repeated measurements of acute re-
jection grade were analyzed longitudinally using nonlinear mixed model-
ing with temporal decomposition as described for spirometry.
Presentation. Continuous variables are summarized by mean  stan-
dard deviation unless distributions are skewed, in which case median and
(for consistency) 15th and85th percentiles are given. Regression coefficients
are accompanied by 1 standard error. For consistency, time-related esti-
mates are accompanied by 68% confidence limits equivalent to1 standard
error. Categorical variables are summarized by frequency and percentage.RESULTS
GERD Associations
Of the patients with pretransplant pH testing (n ¼ 114),
32 (28%) were identified as having GERD (Table 1).
Only 3 (9.4%) had GERD symptoms at transplant, although
7 (22%) patients were receiving acid suppression therapy.
Despite a thorough investigation of associated factors, in-
cluding age, etiology of lung failure, smoking history, and
body mass index, among others, no reliable associations
with GERD were identified.GERD and Spirometry
There was gradual improvement in FEV1% early after
transplant that plateaued after about 6 months (Figure 1).
Pretransplant GERD was associated with decreased FEV1
early after lung transplantation (Table E1). Specifically, by
18 months after transplant, pretransplant GERDwas associ-
ated with a decrease of FEV1% from 83% in double lung
transplant without GERD to 70% with GERD, and from
60% in single lung transplant without GERD to 50% with
GERD (Figure 2). Apparently, maximum FEV1 for double
lung transplant recipients with GERD is not demonstrably
better than after single lung transplant for patients without
GERD. The spirometry advantage of double lung transplant
was importantly abrogated by GERD. Thus, the difference
in FEV1 between them at 12 months was 70% versus 61%.ry c July 2011
TABLE 1. Patient and transplant details according to presence or absence of pretransplant GERD
Characteristic
GERD
(total n ¼ 32)
No GERD
(total n ¼ 82)
P valuen* No. (%) or mean ± SD N* No. (%) or mean ± SD
Demographic
Women 32 9 (28) 82 33 (40) .2
Age (y) 32 56  13 82 54  10 .02
BMI (kg $ m2) 32 25  4.3 80 25  4.9 .6
Comorbidities
History of smoking 32 23 (72) 82 56 (68) .7
Creatinine (mg $ dL1) 27 0.73  0.18 73 0.75  0.23 .9
Diabetes 25 4 (16) 64 11 (17) .9
Pulmonary function
Preoperative FEV1 (% of predictedy) 32 33  18 81 32  17 .7
Etiology of lung failure 32 81
COPD or alpha-1 antitrypsin deficiency 15 (47) 30 (37) .3
Idiopathic pulmonary fibrosis 11 (34) 33 (41) .5
Cystic fibrosis or bronchiectasis 4 (13) 12 (15) .8
Sarcoidosis 0 (0) 2 (2.5) .4
Other 2 (6.3) 4 (4.9) .8
Surgical
Double lung transplant 32 17 (53) 82 59 (72) .06
Maximum ischemic time (min) 31 297  81 74 291  68 .9
GERD, Gastroesophageal reflux disease; SD, standard deviation. BMI, body mass index; FEV1, forced 1-second expiratory volume; COPD, chronic obstructive pulmonary
disease. *Patients with data available. yNational Health and Nutrition Examination Survey normalized.
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Therewerenoevidentdifferences inmodesofdeathbetween
GERD and no GERD patients, with infection, respiratory fail-
ure, and graft failure predominating (Table E2). Unadjusted
survival after lung transplantation at 1, 3, 6, and 12 months
for patients without GERD was 99%, 94%, 90%, and 87%
versus 94%, 91%, 75%, and 75% for patients with GERDFIGURE 1. Estimated mean forced 1-second expiratory volume (FEV1) ex
gastroesophageal reflux disease (GERD). Symbols represent crude depiction
68% confidence limits for the mean.
The Journal of Thoracic and C(P[log-rank] ¼ .02; Figure 3); however, events were too few
to differentiate this as an early or late effect (Table E1).
GERD and Acute Rejection
Presence of pretransplant GERD did not affect acute re-
jection grade or freedom from rejection over the first 18
months after transplant (Table E1; Figure 4).pressed as a percent of predicted, stratified by presence or absence of
s of raw data unadjusted for repeated measures. Dashed lines represent
ardiovascular Surgery c Volume 142, Number 1 49
FIGURE 2. Estimated mean forced 1-second expiratory volume (FEV1) after lung transplantation according to double versus single lung transplant and
presence or absence of gastroesophageal reflux disease (GERD).
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Pretransplant GERD is associated with deleterious early
outcomes after lung transplantation. These early effects are
manifested principally as a marked decrease in maximum
posttransplant FEV1% and higher 1-year mortality. These
findings suggest that preexistingGERDmight serve as a crit-
ical inflection point around which therapeutic intervention
might importantly improve lung transplant outcome.
The mechanism of the process, surprisingly, does not ap-
pear to involve an increase in acute rejection frequency orFIGURE 3. Survival after lung transplantation according to presence or abse
a death, vertical bars confidence limits equivalent to 1 standard error, and nu
50 The Journal of Thoracic and Cardiovascular Surgeseverity, as has been suggested by others.1-3 However, the
present study differs because of pretransplant and not
posttransplant assessment of GERD, and the analysis
accounted for results from every single spirometric test
and biopsy performed after transplant. Furthermore, effect
of pretransplant GERD does not appear to be associated
with age, etiology of lung failure, or whether a single or
double lung transplant was performed.
A high prevalence of GERD in patients with end-stage
lung disease, particularly those awaiting pulmonarynce of gastroesophageal reflux disease (GERD). Each symbol represents
mbers in parentheses patients remaining at risk.
ry c July 2011
FIGURE 4. Proportion of patients in vascular rejection grade 0 after lung transplantation according to presence or absence of gastroesophageal reflux dis-
ease (GERD). The format is as in Figure 1, except confidence bands have been suppressed for clarity.
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combination with appreciation that reflux is common after
transplant and linked to BOS, suggests that it may be an
important mediator of chronic lung injury before
transplant and play a role in the complex cascade of
events leading to allograft dysfunction after transplant.
Mounting evidence supports a central role for GERD in
lung injury; that fundoplication both before and after lung
transplant appears beneficial clearly strengthens this
contention.15 Although it is unknown whether reflux identi-
fied before transplant faithfully translates after transplant,
our results suggest it probably does.
Prevalence of pretransplant GERD in this series is consis-
tent with that reported elsewhere14 but far below that re-
ported after lung transplantation.1 There are likely
multiple reasons for this, including iatrogenic vagal nerve
injury, medications, and pleural pressure changes after
transplant. Esophageal dysmotility, lower esophageal
sphincter relaxation, and delayed gastric emptying might
all collaborate to magnify preexisting GERD after trans-
plant or create the process de novo. Pretransplant symptoms
of GERD did not correlate well with objective assessments
or with use of acid suppression therapy and should not be
used as a surrogate for GERD after transplant.
In light of these ‘‘difficult-to-quantify’’ factors poten-
tially arising after transplant, it was surprising to us that pre-
transplant GERD still emerged as such an important
predictor of outcome. Our initial plan was to reassess
GERD after transplant, allowing us to understand the pro-
cess more thoroughly and better appreciate the contribution
of the transplant to GERD. However, it quickly became ap-The Journal of Thoracic and Cparent that postoperative reflux studies were even more dif-
ficult to obtain than preoperative ones for many of the same
reasons detailed in the ‘‘Methods’’ section. It is our belief
that posttransplant assessment would be far more informa-
tive; however, its timing becomes complicated given the
highly variable postoperative course of patients, especially
as preoperative acuity of illness has increased with the lung
allocation score system. The impact of pretransplant GERD
is an early phenomenon, and although our pH measure-
ments clearly highlighted a population at risk, more accu-
rate information about patients at risk after transplant is
critical.
We have not adopted broad application of fundoplication
early after transplant. Fundoplication, even if performed
laparoscopically, is a substantial undertaking. When fundo-
plication has been performed after lung transplantation by
others, few procedures occurred in the first 3 months.16 In
the cohort of patients for whom posttransplant fundoplica-
tion was found to retard development of BOS, pH testing
was obtained an average of 500 days after transplant.1 Be-
cause our findings suggest an early impact of GERD (within
the first year), this phenomenon was likely perhaps not ad-
dressed in any prior study.
Even now, when pretransplant GERD is identified, we
have reserved fundoplication for patients inwhom the trajec-
tory of postoperative FEV1 has probably plateaued. This has
resulted in few posttransplant fundoplications, most often in
the setting of large hiatal hernias. Perhaps it is time to revisit
this treatment strategy and become more aggressive.
Impact of pretransplant GERD on development of BOS is
unclear, and longer follow-up of our cohort is necessary toardiovascular Surgery c Volume 142, Number 1 51
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reference point between patients with and without GERD
may factor into future diagnosis of BOS because, currently,
there is no accounting for the decrement in spirometry ex-
pected for patients with GERD.
The study suggests that pretransplant GERD may nega-
tively affect survival. It is reasonable to believe that this is
mediated by a direct effect of GERD on allograft function,
as has been demonstrated. Depending on the actual mecha-
nism, it is conceivable that presence of GERD lessens the
survival advantage of double over single lung transplant
that has been reported.17
The mechanism of graft dysfunction in patients with pre-
transplant GERD is unclear. We have examined a variety of
possible culprits, including rejection, but have found none
that appears to be associated with GERD. Whether this re-
flects inadequacy of our histopathologic characterization of
biopsy specimens or whether early rejection and the phe-
nomenon we are reporting are truly 2 distinct entities re-
mains undetermined. Correlation of biopsy results with
bronchoalveolar lavage specimens (bile) might clarify an
association with declining spirometry. Humoral rejection
was not interrogated in these patients and cannot be com-
mented on.
Limitations
Reflux studies were not obtained on all transplant candi-
dates, nor were they obtained at similar intervals from trans-
plant in those patients studied. We have assumed that
regardless of time interval to transplant, patients were not
identified as transient refluxers, but rather as chronically af-
flicted. There may have been a subtle bias in the selection of
patients able to be assessed for reflux (Figure E3), as well as
institutional differences in pH testing. We attempted to con-
trol the latter by distilling the data down to a dichotomous
variable: reflux yes–no. We appreciate that quantitative
data for all patients would have been ideal. However,
even at our own institution, where quantitative data accom-
pany each pH study, a final gastroenterology interpretation
was recorded as reflux yes–no. Lack of quantitative data is
a limitation, particularly in terms of the depth of analysis
that was possible. Additional markers for reflux, such as
manometry and gastric emptying studies, although obtain-
able at our own institution, were rarely available from refer-
ring centers. Clearly, addition of these contributors to reflux
would have enhanced this study.
This study highlights the importance, yet difficulties, of
routine pretransplant GERD testing. Because of the find-
ings, we have become more fastidious regarding collecting
these important data and have begun to use endoscopic cap-
sule assessment among patients with intractable cough to52 The Journal of Thoracic and Cardiovascular Surgereduce errors or noncompliance encountered with conven-
tional pH pretransplant testing.
CONCLUSIONS
For lung transplant recipients, pretransplant GERD is as-
sociated with worse early allograft function and survival,
but not increased perivascular acute rejection. The compro-
mise in lung function is substantial, such that FEV1 after
double lung transplant in GERD patients approaches that
of single lung transplant in non-GERD patients. We advo-
cate thorough testing for GERD before lung transplantation;
if identified, aggressive therapy early after transplant, in-
cluding fundoplication, may prove efficacious.
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APPENDIX E1. Patient variables used in analysis*
Demographic Gender, age (y),* body mass index (kg $ m2),* race
Comorbidities Smoking, creatinine (mg $ dL1),* diabetes, hypertension
Serology Blood type (A, AB, B, O, Rhþ), panel reactive antibody
Hemodynamics Cardiac output (L $min1), cardiac index (L $min1 $m2), blood pressure (diastolic,* systolic,* mean; mm Hg), pulmonary
arterial pressure (diastolic, systolic, mean; mm Hg)
Pulmonary function Preoperative FEV1 (% of predicted)
Diagnosis Cystic fibrosis/bronchiectasis, chronic obstructive pulmonary disease/emphysema/alpha-1 antitrypsin deficiency,* idiopathic
pulmonary fibrosis*
Surgical Double lung transplant, ischemic time (min)
Experience Interval from listing to transplant (d), interval from January 1, 2005 to transplant (y)*
*Asterisks indicate variables included in semisaturated propensity model.
FIGUREE1. Number of patients with forced 1-second expiratory volume
(FEV1) measurements available at and beyond various time points, and
number of FEV1 measurements available for analysis. A, Patients with gas-
troesophageal reflux disease. B, Patients without gastroesophageal reflux
disease.
FIGURE E2. Number of patients with biopsy tissue available at and be-
yond various time points, and number of biopsy results available for anal-
ysis. Also shown is percentage of evaluable patients with biopsies. A,
Patients with gastroesophageal reflux disease. B, Patients without gastro-
esophageal reflux disease.
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FIGURE E3. Survival after lung transplantation according to pH test availability. Format is as in Figure 4.
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TABLE E1. Unadjusted and propensity score–adjusted outcomes
after lung transplantation in patients with and without GERD
Phase Variable Estimate ± SE
P
value
FEV1
Unadjusted
Early GERD 0.64  0.20 .001
Constant GERD 0.15  0.40 .7
Propensity adjusted
Early GERD 0.56  0.20 .01
Constant GERD 0.11  0.10 .9
FEV1 and type of transplant
Unadjusted
Early GERD and SLTx 0.91  0.50 .09
GERD and DLTx 0.41  0.20 .1
No GERD and DLTx 0.81  0.20 <.0001
Constant GERD and SLTx 0.071  0.10 .6
GERD and DLTx 0.021  0.10 .8
No GERD and DLTx 0.022  0.10 .9
Propensity adjusted
Early GERD and SLTx 0.79  0.50 .1
GERD and DLTx 0.43  0.20 .09
No GERD and DLTx 0.81  0.10 <.0001
Constant GERD and SLTx 0.091  0.10 .5
GERD and DLTx 0.021  0.10 .9
No GERD and DLTx 0.022  0.10 .9
Survival
Unadjusted
Early GERD 0.91  0.60 .1
Late GERD 0.74  0.70 .3
Propensity adjusted
Early GERD 0.60  0.50 .2
Late GERD 1.07  0.90 .3
Rejection
Unadjusted
Early GERD 0.22  0.40 .6
Late GERD 0.32  0.30 .3
Propensity adjusted
Early GERD 0.55  0.40 .9
Late GERD 0.14  0.30 .6
GERD, Gastrointestnal reflux disease; SE, standard error; FEV1, forced 1-second ex-
piratory volume; SLTx, single lung transplant; DLTx, double lung transplant.
TABLE E2. Mode of death after lung transplantation
Primary mode of death
GERD No GERD
No. % of 12 No. % of 16
Infection 4 33 3 19
Respiratory failure 3 25 3 19
Graft failure 1 8.3 2 12
Cardiac arrest 1 8.3 1 6.2
Cancer 0 2 12
Bronchiolitis 1 8.3 0
Multisystem organ failure 1 8.3 0
Graft dehiscence 0 1 6.2
Pulmonary embolism 0 1 6.2
Hemorrhage 1 8.3 0
Unspecified 0 3 19
Total 12 100 16 100
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